美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NETLease Corporate Real Estate ETF

26.79

+0.18100.68%

盤後：26.810.0190+0.07%19:30 EDT

成交量：7,452

成交額：19.94萬

市值：5,559.13萬

市盈率：- -

高：26.81

開：26.81

低：26.68

收：26.61

52周最高：28.43

52周最低：23.56

股本：207.50萬

流通股本：207.50萬

量比：0.68

換手率：0.36%

股息：1.25

股息率：4.67%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Realty Income公司上調2026年每股AFFO指引，中點增速約達4%

22億美元ADC出海改寫康寧傑瑞

国际金融报

港股異動 | 百奧賽圖-B(02315)升逾10% 雙抗ADC推進海外開發臨床前CRO與模型鼠景氣度上行

康寧傑瑞製藥-B早盤升逾12% TROP2/HER3雙抗ADC授權出海

中國生物製藥(01177)：TQB2102「HER2雙抗ADC」第三次被CDE納入突破性治療藥物名單

港股異動 | 百奧賽圖-B(02315)午後升逾8% 近期與Whitehawk達成合作旗下5款雙抗ADC出海

智通财经网

李氏大藥廠：專有ADC項目ZK2401新藥臨床試驗申請獲NMPA受理

AvalonBay Communities（AVB）與Equity Residential（EQR）合併房地產投資信託基金預估市值可達530億美元

科倫藥業(002422.SZ)：TROP2 ADC蘆康沙妥珠單抗(sac-TMT)新增適應症上市申請獲受理

受租金收入增長提振，VICI上調了2026年基金運營收入（FFO）預測

VICI Properties 更新2026財年調整後運營資金指引：上調至26.75億-27億美元，每股2.45-2.47美元

Sonesitatug vedotin 在 CLDN18.2陽性晚期胃癌/胃食管結合部癌的二線及後線治療中，顯示出具有統計學顯著性且重要臨床意義的總生存期（OS）改善

科倫藥業(002422.SZ)：科倫博泰新型雙載荷ADC藥物SKB565新藥臨床試驗(IND)申請獲批

英派藥業首個雙載荷ADC成果落地：IMP3201被提名為臨床前候選化合物

百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)臨床試驗完成首例受試者入組

Biohaven將在ESMO大會公布BHV-1530 ADC新藥臨床數據

环球市场播报

科倫博泰TROP2 ADC實現「全球首個」：PD-L1陰性一線NSCLC III期達PFS主要終點

每日经济新闻

消息人士稱，AirTrunk計劃於9月或10月在新加坡推出房地產投資信託基金首次公開發行，有望籌資約15億美元。

美國研究綜述-Equinix、高盛、摩根大通

科倫藥業：TROP2 ADC聯合療法肺癌3期臨床達主要終點

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/NETL/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NETL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","market":"US","secType":"STK","nameCN":"NETLease Corporate Real Estate ETF","latestPrice":26.791,"timestamp":1787601600000,"preClose":26.61,"halted":0,"volume":7452,"hourTrading":{"tag":"盘后","latestPrice":26.81,"preClose":26.791,"latestTime":"19:30 EDT","volume":9,"amount":241.119,"timestamp":1787614206571,"change":0.019,"changeRate":0.000709,"amplitude":0},"delay":0,"changeRate":0.006801954152574256,"floatShares":2075000,"shares":2075000,"eps":0,"marketStatus":"已收盤","change":0.181,"latestTime":"08-24 16:00:00 EDT","open":26.8094,"high":26.81,"low":26.6796,"amount":199439.768808,"amplitude":0.0049,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":26.61,"sharesOutstanding":1775000,"nav":26.54,"aum":55070500,"dividendRate":0.046684,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.81,"preClose":26.791,"latestTime":"19:30 EDT","volume":9,"amount":241.119,"timestamp":1787614206571,"change":0.019,"changeRate":0.000709,"amplitude":0},"volumeRatio":0.683971,"impliedVol":0.0633,"impliedVolPercentile":0.0438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","floatShares":2075000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.683971,"shares":2075000,"dividePrice":1.2507,"high":26.81,"amplitude":0.0049,"preClose":26.61,"low":26.6796,"week52Low":23.56,"pbRate":"--","week52High":28.4299,"institutionHeld":0,"latestPrice":26.791,"eps":0,"divideRate":0.046684,"volume":7452,"delay":0,"ttmEps":0,"open":26.8094,"prevYearClose":23.727,"prevWeekClose":26.61,"prevMonthClose":27.14,"prevQuarterClose":26.7001,"fiveDayClose":26.48,"twentyDayClose":27.9307,"sixtyDayClose":26.3675},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NETL\",params:#limit:5,,,undefined,":[{"date":"2026-07-29","symbol":"NETL","amount":0.105,"announcedDate":"2026-07-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-29","defaultRemindTime":1785331800000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-31","payableDate":"2026-07-29","currency":"USD","dateTimestamp":1785297600000,"payDate":"2026-07-31"},{"date":"2026-06-26","symbol":"NETL","amount":0.105,"announcedDate":"2026-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-26","defaultRemindTime":1782480600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-26","currency":"USD","dateTimestamp":1782446400000,"payDate":"2026-06-30"},{"date":"2026-05-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-05-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-27","defaultRemindTime":1779888600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-27","currency":"USD","dateTimestamp":1779854400000,"payDate":"2026-05-29"},{"date":"2026-04-28","symbol":"NETL","amount":0.105,"announcedDate":"2026-04-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-28","defaultRemindTime":1777383000000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-30","payableDate":"2026-04-28","currency":"USD","dateTimestamp":1777348800000,"payDate":"2026-04-30"},{"date":"2026-03-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-27","defaultRemindTime":1774618200000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-27","currency":"USD","dateTimestamp":1774584000000,"payDate":"2026-03-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NETL\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-30","recordDate":"2019-12-31","paymentDate":"2020-01-02","value":0.031935,"currency":"USD"},{"executeDate":"2020-03-17","recordDate":"2020-03-18","paymentDate":"2020-03-19","value":0.0097783,"currency":"USD"},{"executeDate":"2020-03-31","recordDate":"2020-04-01","paymentDate":"2020-04-02","value":0.1912399,"currency":"USD"},{"executeDate":"2020-06-26","recordDate":"2020-06-29","paymentDate":"2020-06-30","value":0.2782635,"currency":"USD"},{"executeDate":"2020-09-15","recordDate":"2020-09-16","paymentDate":"2020-09-30","value":0.2792338,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NETL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NETL\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1153061120","title":"Realty Income公司上調2026年每股AFFO指引，中點增速約達4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153061120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153061120?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 04:20","pubTimestamp":1785961203,"startTime":"0","endTime":"0","summary":"Realty Income Corporation发布最新动态：其2026年调整后运营资金（AFFO）每股指引已获上调。分析指出，这一调整后的指引中点，所反映的增长率大约为4%。这表明，公司对未来盈利能力的预期正趋于乐观。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NETL","SRHR","ERET","TSRS","BK4080","DFAR","BK4231","DPRE","RWR","BK4585","CLIM","O","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657516276","title":"22億美元ADC出海改寫康寧傑瑞","url":"https://stock-news.laohu8.com/highlight/detail?id=2657516276","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657516276?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:09","pubTimestamp":1785913740,"startTime":"0","endTime":"0","summary":"站在行业发展的角度看，双抗ADC，正在成为国产创新药出海的全新增长极。8月4日，康宁杰瑞生物制药发布重磅公告，旗下全球首创TROP2/HER3双特异性抗体偶联药物（ADC）JSKN016达成海外独家授权合作，与美国AI驱动肿瘤新药研发企业PathosAI签约，交易总潜在金额最高达22.18亿美元（约合142.2亿元），创下国产双抗ADC出海的新里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832538126.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832538126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2357305700.SGD","LU0348723411.USD","LU1804176565.USD","CNAV","LU2473716301.USD","LU2543165471.USD","BK4148","NETL","LU1992135399.USD","LU2272731600.USD","BK4512","GLWG","LU2272731782.SGD","LU1720051017.SGD","LU2322448791.USD","LU2322448957.HKD","GLW","BK4585","LU1992135472.HKD","BK4080","LU1720051108.HKD","LU1548497426.USD","ADC","RULE","BK4588","BK4231","LU2272731865.HKD","LU2265009873.SGD","IE00BFMHRM44.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656538672","title":"港股異動 | 百奧賽圖-B(02315)升逾10% 雙抗ADC推進海外開發 臨床前CRO與模型鼠景氣度上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2656538672","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656538672?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 15:00","pubTimestamp":1785826839,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超10%，截至发稿，涨10.39%，报57.9港元，成交额8028.46万港元。消息面上，百奥赛图上月宣布与Whitehawk Therapeutics, Inc.签署一项全球战略合作协议，涵盖多个双特异性抗体偶联药物研发项目，双方将共同推进多元化的新一代治疗产品管线。据悉，从双方正式启动合作到完成协议签署，历时仅仅约四个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","ADC","KCAI","02315","BK1161","688796","BK0216","BK4231","BK4585","BK4080","BK4588","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656963586","title":"康寧傑瑞製藥-B早盤升逾12% TROP2/HER3雙抗ADC授權出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2656963586","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656963586?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 09:54","pubTimestamp":1785808440,"startTime":"0","endTime":"0","summary":"模拟交易客户端康宁杰瑞制药-B早盘涨超12%，截至发稿，股价上涨12.43%，现报8.32港元，成交额762.18万港元。康宁杰瑞生物制药宣布，其全资子公司江苏康宁杰瑞生物制药有限公司与Pathos AI， Inc．就康宁杰瑞自主研发的同类首创新药TROP2/HER3双特异性抗体偶联药物JSKN016达成授权许可协议。作为本次授权合作的一部分，康宁杰瑞获得Pathos授予的一份认股权证，有权认购Pathos的优先股股份，认购总价为6，250万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzt5433129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","ADC","09966","BK1161","BK4231","BK4080","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656248463","title":"中國生物製藥(01177)：TQB2102「HER2雙抗ADC」第三次被CDE納入突破性治療藥物名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2656248463","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656248463?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 16:37","pubTimestamp":1785746238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB2102“HER2双抗 ADC”已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物名单，用于在复发或转移性疾病阶段未接受过化疗的不可切除或转移性HER2低表达成人乳腺癌患者。这是继HER2阳性早期乳腺癌新辅助治疗、HER2 IHC 3+晚期结直肠癌之后，TQB2102获得的第三项突破性疗法认定，进一步印证了其在HER2表达实体瘤治疗领域的广泛应用潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","HK0000165453.HKD","01177","IE00BZ08YT58.USD","BK1191","BK1521","LU1223083913.SGD","CDE","NETL","GDXJ","SGDM","LU1223082196.USD","LU1223082519.USD","BK4231","IE00BZ08YS42.EUR","BK4017","IE00BZ08YR35.GBP","XME","BK1589","SIL","BK4080","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656432314","title":"港股異動 | 百奧賽圖-B(02315)午後升逾8% 近期與Whitehawk達成合作 旗下5款雙抗ADC出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2656432314","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656432314?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 14:28","pubTimestamp":1785738520,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B午后涨超8%，截至发稿，涨6.28%，报53.3港元，成交额5248.07万港元。消息面上，近日，百奥赛图与Whitehawk Therapeutics达成一项全球战略合作协议，涵盖多个双特异性抗体偶联药物研发项目，双方将共同推进新一代治疗产品管线。据悉，Whitehawk将对百奥赛图提供的五款双特异性抗体进行评估，并有权选择将任何由此产生的ADC候选药物推进至其研发管线中，百奥赛图将获得一定数额的首付款及潜在里程碑付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK4231","688796","BK4585","BK4080","VXUS","02315","ADC","BK0216","NETL","BK4588","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655280547","title":"李氏大藥廠：專有ADC項目ZK2401新藥臨床試驗申請獲NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655280547","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655280547?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 22:20","pubTimestamp":1785421250,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NETL","IBBQ","BMED","PSYK","IBBJ","MDTX","ADC","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655806836","title":"AvalonBay Communities（AVB）與Equity Residential（EQR）合併 房地產投資信託基金預估市值可達530億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655806836","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655806836?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 22:15","pubTimestamp":1785420930,"startTime":"0","endTime":"0","summary":"本次合并将打造规模庞大的长租公寓运营平台，合并完成后的房地产投资信托基金预估市值可达530亿美元，企业价值约710亿美元。消息传出后，二级市场股价出现波动，AvalonBay早盘下跌1.4%，Equity Residential股价下跌1.6%，市场持续观望本次合并后续整合方案与运营规划。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303239","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFRA","BK4550","DPRE","AVB","ALTY","NURE","BLDG","CSRE","IVRA","IYLD","SPHD","ASET","BK4007","BK4585","BK4139","KBWD","DTRE","IDGT","CRIB","RITA","BK4588","IQRA","REAI","REZ","AVRE","XSHD","FREI","PPTY","BK4215","INDS","JPRE","VGSR","MDIV","SPRE","GARA","EQR","FPRO","RNTY","RWO","GRI","NETL","HIPS","ABLD","VRAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655712728","title":"科倫藥業(002422.SZ)：TROP2 ADC蘆康沙妥珠單抗(sac-TMT)新增適應症上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655712728","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655712728?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 19:31","pubTimestamp":1785411100,"startTime":"0","endTime":"0","summary":"此前，芦康沙妥珠单抗用于一线治疗不可手术切除的局部晚期、复发或转移性PD-L1阴性TNBC已获NMPA授予突破性疗法认定。本次新增适应症上市申请亦已纳入优先审评审批程序，成为芦康沙妥珠单抗纳入该程序的第六项上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1934453819.USD","BK0060","LU1979443071.USD","BK0239","ADC","LU2148510915.USD","LU1064131003.USD","BK4231","BK4080","LU1064130708.USD","NETL","002422","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655881059","title":"受租金收入增長提振，VICI上調了2026年基金運營收入（FFO）預測","url":"https://stock-news.laohu8.com/highlight/detail?id=2655881059","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655881059?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 06:45","pubTimestamp":1785365108,"startTime":"0","endTime":"0","summary":"受租金收入增长提振，VICI上调了2026年基金运营收入预测路透7月29日-VICI Properties上调了2026年调整后运营现金流预测的下限，因该公司在本季度新增了三家租户，从而实现了租金收入来源的多元化和增长。该公司目前预计2026年每股调整后基金运营收益将在2.45美元至2.47美元之间，高于此前预期的2.44美元至2.47美元。不过，VICI本季度每股经调整基金从运营中获得的收益为62美分，低于分析师预期的每股67美分该股在盘后交易中下跌0.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4T43V2PN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GQRE","BK4084","TSRS","VICI","BK4585","NETL","BK4234","BK4588","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171830503","title":"VICI Properties 更新2026財年調整後運營資金指引：上調至26.75億-27億美元，每股2.45-2.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171830503","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171830503?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 05:09","pubTimestamp":1785359381,"startTime":"0","endTime":"0","summary":"VICI Properties 今日宣布，其2026财年调整后运营资金（Adjusted Funds From Operations）指引已更新。最新预测显示，公司预期该指标总额将达到26.75亿至27亿美元之间。换算为每股收益，则落在2.45美元至2.47美元的区间内。这一调整反映了公司对业务前景的重新评估与信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSRS","BK4585","BK4234","BK4588","GQRE","VICI","NETL","BK4084","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654395072","title":"Sonesitatug vedotin 在 CLDN18.2陽性晚期胃癌/胃食管結合部癌的二線及後線治療中，顯示出具有統計學顯著性且重要臨床意義的總生存期（OS）改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2654395072","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654395072?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 12:18","pubTimestamp":1785212280,"startTime":"0","endTime":"0","summary":"关于胃癌和胃食管结合部癌 胃癌是全球第五大常见癌症，也是癌症相关死亡的第五大原因。关键次要终点为二线及后线治疗人群的总生存期。CLDN18.2是一种存在于胃黏膜上皮中的蛋白，已被验证为肿瘤治疗领域的重要治疗靶点，尤其在胃肠道肿瘤中具有重要意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IBBQ","COAL","HCC","BITI","BTCZ","PFS","EZBC","CBTY","BTCL","CBXY","MAXI","BTRN","BITU","BITY","BETE","BTCO","NETL","HODL","ARKB","BTCW","SBIT","BFJL","CBOJ","CBXJ","AZN","CBXA","BETH","BRRR","CBTA","BITX","BCCC","AZNH","ADC","BITO","CBXO","YBTC","BTC","EAC","BTFX","IHC","CBOA","QBF","MNRS","CBTJ","DEFI","FBTC","XBTY","BTCI","IBIT","CBTO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654224045","title":"科倫藥業(002422.SZ)：科倫博泰新型雙載荷ADC藥物SKB565新藥臨床試驗(IND)申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2654224045","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654224045?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 22:16","pubTimestamp":1785161788,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业 发布公告，公司近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司已收到国家药品监督管理局药品审评中心同意新型双载荷ADC药物SKB565新药临床试验申请的临床试验通知书，用于治疗晚期实体瘤。这是科伦博泰首个进入临床阶段的双载荷抗体偶联药物。据悉，SKB565是科伦博泰“ADC+IO”一体化开发策略的核心代表药物之一，基于科伦博泰专有的OptiDCTM平台开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","NETL","LU1934453819.USD","LU2148510915.USD","002422","ADC","LU1064131003.USD","PSYK","IBBJ","LU1979443071.USD","BK4231","BK4080","IBBQ","BK0239","MDTX","IND","BMED","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654936970","title":"英派藥業首個雙載荷ADC成果落地：IMP3201被提名為臨床前候選化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=2654936970","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654936970?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 09:06","pubTimestamp":1785114360,"startTime":"0","endTime":"0","summary":"7月27日，英派药业（07630）发布公告，宣布IMP3201被提名为临床前候选化合物（PCC），这是基于公司自主研发的双载荷ADC平台的首个成果。IMP3201是一种靶向CEACAM5的双载荷ADC，采用优化的摩尔比搭载Exatecan及公司专有的ATR抑制剂。该化合物旨在治疗胃肠道恶性肿瘤，包括结直肠癌、胰腺癌、胃癌及食管鳞状细胞癌，以满足临床需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273821349058.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273821349058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","NETL","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654639210","title":"百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2654639210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654639210?lang=zh_tw&edition=fundamental","pubTime":"2026-07-26 15:48","pubTimestamp":1785052138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的创新生物药注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中对比T-Bren与医生选择的化疗的III期随机对照临床试验已于近日完成首例受试者入组。据悉，T-Bren是一种靶向HER2的创新型ADC，具有同类最佳潜力，已在临床试验中展示出显著的抗肿瘤功效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4080","IBBJ","BMED","688506","NETL","91194","MDTX","IBBQ","02615","BK4231","PSYK","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652903211","title":"Biohaven將在ESMO大會公布BHV-1530 ADC新藥臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2652903211","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652903211?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 22:25","pubTimestamp":1784557500,"startTime":"0","endTime":"0","summary":"生物制药公司Biohaven周一宣布，将在即将举行的欧洲肿瘤内科学会大会上公布其新型FGFR3靶向抗体偶联药物BHV-1530的临床数据。BHV-1530搭载了公司专有的拓扑异构酶I抑制剂有效载荷。　　Biohaven在新闻稿中表示，此次公布的数据将包括BHV-1530在晚期实体瘤患者中的首次人体临床试验初步结果，重点评估药物的安全性、耐受性和初步抗肿瘤活性。Biohaven的BHV-1530数据将在大会的“新药物”专题环节中以口头报告形式呈现。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-20/doc-iniinmvy8222546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","ADC","NETL","BK4231","BHV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651246129","title":"科倫博泰TROP2 ADC實現「全球首個」：PD-L1陰性一線NSCLC III期達PFS主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2651246129","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651246129?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 22:38","pubTimestamp":1784126286,"startTime":"0","endTime":"0","summary":"7月15日早间，科伦博泰（HK06990，股价536.50港元，市值1282.36亿港元）宣布其TROP2ADC药物芦康沙妥珠单抗（佳泰莱?）联合帕博利珠单抗（可瑞达?）一线治疗PD-L1阴性非鳞状非小细胞肺癌的III期研究（OptiTROP-Lung06）在期中分析中达到无进展生存期主要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807804934.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807804934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4211","NETL","BK4195","BK4080","LU1169589451.USD","ADC","BK4023","BK4231","PD","PFS","BK4134","III","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145968","title":"消息人士稱，AirTrunk計劃於9月或10月在新加坡推出房地產投資信託基金首次公開發行，有望籌資約15億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145968?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 17:39","pubTimestamp":1784108365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["JPRE","RWO","HIPS","ABLD","IYLD","AVRE","BK4588","IQRA","ASET","SPRE","BLDG","NETL","IDGT","REAI","KBWD","BK4550","GRI","BK4007","INDS","MDIV","FPRO","BK4139","VRAI","VGSR","CSRE","XSHD","DTRE","IVRA","SPHD","ALTY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651043069","title":"美國研究綜述-Equinix、高盛、摩根大通","url":"https://stock-news.laohu8.com/highlight/detail?id=2651043069","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651043069?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 15:24","pubTimestamp":1784100290,"startTime":"0","endTime":"0","summary":"美国研究综述-Equinix、高盛、摩根大通路透7月15日-周三，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括Equinix、高盛和摩根大通。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nL4S43H0J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KIM","EQIX","EXR","CHRW","DKUP","KRG","OFG","CHEF","AMT","IDGT","VAN","EGP","NETL","CDP","BPOP","LVS","ADC","DLR","PENN","SRVR","LSTR","FREL","PTCT","LXP","KHC","BRX","AKR","JPM","BYD","PFGC","AIR","MAC","IHF","FBP","VGSR","BXP","DKNG","ITA","CELC","GS","JLL","AHR","IVT","GE","RWR","FRT","LGND","BAC","HCA","CCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651436406","title":"科倫藥業：TROP2 ADC聯合療法肺癌3期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2651436406","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651436406?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 11:58","pubTimestamp":1784087937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4080","BK4231","NETL","ADC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49,"code":"91000000","status":"200"}]}}